课题基金 / 基金详情

HUMAN RHEUMATOID FACTOR CROSS-IDIOTYPES

HUMAN RHEUMATOID FACTOR CROSS-IDIOTYPES
人类类风湿因子跨独特型
批准号:
3138331
负责人:
Vincent Agnello
金额:
$17.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-09-30 至 1990-08-31

项目摘要

项目成果

Vincent Agnello的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The occurrence of the three human monoclonal rheumatoid factor (mRF) cross idiotypes (XIds) WA, PO and BLA among polyclonal rheumatoid factors in various diseases and among immunogobulins in normals will be studied using mouse monoclonal antibodies with specifities for the heat labile conformational heavy-light chain XId antigens that are the main determinants recognized by the original polyclonal antisera which defined the mRF XIds. Occurrence of the mRF XIds in the B cell repertoire will also be accessed. The role of heavy and light chains in forming the XId antigens and in determining the antigen specificities of the mRFs of the three groups will be determined by assorted heavy-light chain recombinations. Studies on the PO XId will persue preliminary data which suggests that this XId determinant, in contrast to the WA and BLA XIds, is not associated with the antigen combining site. Special emphasis will be placed on study of the BLA XId which has been shown to occur in high incidence among polyclonal RFs in rheumatoid arthritis. The RFs bearing this XId have unique specificity in that they react with DNA- histone 2A-2B, antigen in addition to IgG. The amino acid sequence of the variable regions of the light and heavy chains of the prototype monoclonal and polyclonal RFs of this group will be determined in search of insights not only to the structural- idiotype-antigen specificity relationships but also restrictions that may be present in autoantibody production. The occurrence of various mRF complementary determining region (CDR) antigens on polyclonal rheumatoid factors, other polyclonal autoantibodies and normal immunoglobulins using antisera raised to synthetic CDR peptides will be determined to test the hypothesis that certain CDR antigens are selectively associated with autoantibodies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HEPATITIS C VIRUS IN ETIOLOGY OF WA RHEUMATOID FACTORS
  • 批准号:
    6373588
  • 项目类别:
  • 资助金额:
    $23.37万
  • 财政年份:
    1999
  • 负责人:
    Vincent Agnello
  • 依托单位:
HEPATITIS C VIRUS IN ETIOLOGY OF WA RHEUMATOID FACTORS
  • 批准号:
    2852893
  • 项目类别:
  • 资助金额:
    $23.02万
  • 财政年份:
    1999
  • 负责人:
    Vincent Agnello
  • 依托单位:
HEPATITIS C VIRUS IN ETIOLOGY OF WA RHEUMATOID FACTORS
  • 批准号:
    6169771
  • 项目类别:
  • 资助金额:
    $22.81万
  • 财政年份:
    1999
  • 负责人:
    Vincent Agnello
  • 依托单位:
HEPATITIS C VIRUS IN ETIOLOGY OF WA RHEUMATOID FACTORS
  • 批准号:
    6326307
  • 项目类别:
  • 资助金额:
    $9.03万
  • 财政年份:
    1999
  • 负责人:
    Vincent Agnello
  • 依托单位:
国内基金
海外基金
自供能传感阵列同步量化游离DNA与PSA实现前列腺癌的诊断和预后判断
  • 批准号:
    JCZRLH202601177
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
二氢杨梅素通过线粒体代谢重编程抑制DNA同源重组修复逆转口腔癌细胞放疗抵抗的机制研究
  • 批准号:
    2026JJ80500
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    阳帆
  • 依托单位:
乳酸通过ESM1-Akt-MDM2-p53通路调控卵巢癌DNA损伤和抗肿瘤免疫应答的分子机制研究
  • 批准号:
    2026JJ81975
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    肖娇
  • 依托单位:
淫羊藿苷通过TET2介导DNA去甲基化调控Hippo-YAP/TAZ通路逆转绝经后骨质疏松症成血管-成骨耦联失衡的机制研究